14. Chronic inflammatory demyelinating polyneuropathy Clinical trials / Disease details


Clinical trials : 175 Drugs : 161 - (DrugBank : 41) / Drug target genes : 13 - Drug target pathways : 24

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-002783-24-GB
(EUCTR)
25/05/200631/03/2006Prednisolone versus Dexamethasone in Chronic inflammatory demyelinating polyradiculoneuropathy Trial; PREDICT-trial - PREDICT trialPrednisolone versus Dexamethasone in Chronic inflammatory demyelinating polyradiculoneuropathy Trial; PREDICT-trial - PREDICT trial Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated disorder. CIDP is characterised by motor and/or sensory symptoms and signs in more than one limb, developing over at least two months. The disease runs a progressive, relapsing-remitting or monophasic course. The diagnosis of CIDP is based on the clinical, electrophysiological, cerebrospinal fluid features and, to a limited degree, on histopathology.Product Name: dexamethasone
Product Code: dexamethasone
INN or Proposed INN: Dexamethasone
Product Name: Prednisolone
Product Code: Prednisolone
INN or Proposed INN: Prednisolone
Product Name: Prednisolone
Product Code: Prednisolone
INN or Proposed INN: Prednisolone
Product Name: Prednisolone
Product Code: Prednisolone
INN or Proposed INN: Prednisolone
Product Name: Prednisolone
Product Code: Prednisolone
INN or Proposed INN: Prednisolone
Product Name: Prednisolone
Product Code: Prednisolone
INN or Proposed INN: Prednisolone
AMC Medical research BVNULLNot RecruitingFemale: yes
Male: yes
52United Kingdom